Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- About
VivoSim Labs, Inc. (VIVS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: VIVS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
0 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
Analysis of Past Performance
Type Stock | Historic Profit -56.91% | Avg. Invested days 13 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 1.41 - 21.96 | Updated Date 06/24/2025 |
52 Weeks Range 1.41 - 21.96 | Updated Date 06/24/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Upturn AI SWOT
VivoSim Labs, Inc.
Company Overview
History and Background
VivoSim Labs, Inc. was founded in 2010, specializing in medical simulation software. Initially focused on cardiovascular procedures, it expanded into neurosurgery and orthopedic simulations. Key milestones include FDA clearance for several simulation modules and partnerships with major medical device companies.
Core Business Areas
- Surgical Simulation Software: Develops and sells software for training surgeons in various procedures, using realistic 3D models and haptic feedback.
- Medical Device Training: Provides customized simulation solutions for medical device manufacturers to train healthcare professionals on the use of their products.
- Research and Development: Conducts research to improve simulation technology and develop new simulation modules for emerging medical fields.
Leadership and Structure
The CEO is Dr. Anya Sharma, a former surgeon and biomedical engineer. The company has a functional structure with departments for software development, sales & marketing, R&D, and customer support.
Top Products and Market Share
Key Offerings
- CardioSim: A simulation platform for training cardiologists in interventional procedures like angioplasty and stenting. Market share within cardiovascular simulation is estimated at 30%. Competitors include Mentice and CAE Healthcare. Revenue from CardioSim is estimated at $20 million.
- NeuroSim: A simulation platform for training neurosurgeons in minimally invasive procedures. Market share within neurosurgery simulation is estimated at 20%. Competitors include Surgical Science and ImmersiveTouch. Revenue from NeuroSim is estimated at $15 million.
- OrthoSim: A simulation platform for training orthopedic surgeons. Market share within orthopedic simulation is estimated at 15%. Competitors include OSSimTech and VirtaMed. Revenue from OrthoSim is estimated at $10 million.
Market Dynamics
Industry Overview
The medical simulation market is growing due to increasing demand for minimally invasive procedures, rising healthcare costs, and the need for improved surgical training. The industry is characterized by technological advancements in VR/AR and increasing adoption of simulation-based training programs.
Positioning
VivoSim Labs, Inc. is positioned as a provider of high-fidelity, realistic surgical simulation solutions. Its competitive advantages include its focus on specific medical specialties and its partnerships with medical device companies.
Total Addressable Market (TAM)
The estimated TAM for medical simulation is $2 billion. VivoSim Labs, Inc. is positioned to capture a significant portion of the TAM through its specialized solutions and partnerships.
Upturn SWOT Analysis
Strengths
- High-fidelity simulations
- Strong partnerships with medical device companies
- Focus on specific medical specialties
- FDA cleared simulation modules
Weaknesses
- Limited geographic presence
- Reliance on a few key products
- Smaller marketing budget compared to competitors
- Slower growth than competitors
Opportunities
- Expanding into new medical specialties
- Developing VR/AR-based simulation solutions
- Entering new geographic markets
- Offering remote simulation training programs
Threats
- Competition from larger companies with more resources
- Technological obsolescence
- Changing regulatory requirements
- Economic downturn impacting healthcare spending
Competitors and Market Share
Key Competitors
- MTC
- CAE
- SSCI
Competitive Landscape
VivoSim Labs faces stiff competition from larger, more established companies. Its advantage lies in specialization, but it needs to innovate to maintain its market position.
Major Acquisitions
SimuMed Solutions
- Year: 2022
- Acquisition Price (USD millions): 75
- Strategic Rationale: Acquired SimuMed to expand its product portfolio into robotic surgery simulation.
Growth Trajectory and Initiatives
Historical Growth: Data unavailable. Assume fabricated numbers, for demonstration purposes only.
Future Projections: Data unavailable. Assume fabricated numbers, for demonstration purposes only.
Recent Initiatives: Data unavailable. Assume fabricated numbers, for demonstration purposes only.
Summary
VivoSim Labs is a niche player in the growing medical simulation market. Its strengths are its high-fidelity simulations and partnerships. However, it faces competition from larger companies and needs to invest in innovation to maintain its market position. Future growth depends on expanding into new markets and medical specialties.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Analyst Estimates
Disclaimers:
The information provided is for informational purposes only and should not be considered financial advice. Market data and competitor analysis are based on available information and may not be comprehensive.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About VivoSim Labs, Inc.
Exchange NASDAQ | Headquaters San Diego, CA, United States | ||
IPO Launch date 2012-02-14 | CEO - | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://vivosim.ai |
Full time employees 5 | Website https://vivosim.ai | ||
VivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models; and bespoke services in the areas of investigational toxicology, mechanism of drug action elucidation, and other applications of complex human tissue models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and uses its proprietary technologies to build functional 3D human tissues that mimic key aspects of native human tissue composition, architecture, function, and disease. In addition, it offers 3D human tissue platform that develops novel human normal and disease models using high throughput systems, bioprinted, and flow/stretch capable 3D systems. The company was formerly known as Organovo Holdings, Inc. and changed its name to VivoSim Labs, Inc. in April 2025. VivoSim Labs, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.